Fig. 9

Expression of the leukocyte marker PTPRC/CD45 in rat LSECs. a: Ptprc/Cd45 mRNA and PTPRC/CD45 protein expression as obtained from RNA-seq (log₂ RPKM) and label-free proteomics (log₂ iBAQ) in KCs (red dots) and LSECs (blue triangles). b-f: Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1/FcγRIIb2, CD31, and CD45 (listed in Table 1). b: Gating based on the FSC-A vs FSC-H profile to exclude duplets and aggregates from the subsequent analysis. c: Gating on the SSC-A vs FSC-A profile to select small cells with limited complexity (enriched in endothelial cells). d: Gating to select DAPI negative live cells. e-f: LSECs were then identified as SE-1-Alexa488⁺ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45⁺ CD31⁺ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file 8. g: Average of the percentage of viable parent populations observed in 4 biological replicates (±standard deviation, SD)